Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lab21 Announces Sale of South Carolina Operations

Published: Tuesday, April 23, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Company announces sale of its laboratory operations to Reedy Acquisitions Corp.

Lab21 Limited has announced the sale of its laboratory operations based in South Carolina to Reedy Acquisitions Corp, an entity formed by the existing local management and South Carolina based investors.

In addition to an immediate cash benefit for Lab21 Ltd, the sale will remove a loss-making business from the Lab21 Group.

The sale was completed at the end of 2012 and no financial details will be disclosed.

Susan Lowther, CFO of Lab21 Ltd said: “After three years of developing the clinical service business in South Carolina, the Group has taken the decision to sell the laboratory operations in Greenville and Columbia. This sale does not impact our core strategy to focus on personalized medicine and Lab21 will continue to focus on diagnostic content strategy opportunities within the US market.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.
Tuesday, February 26, 2013
Clydesdale Bank £5 Million Funding to Support Lab21 International Growth
Lab21 is expected to deliver greater than 30% revenue growth in 2012.
Tuesday, July 10, 2012
Lab21 Secures European and USA Patents for HCV Drug Resistance Genotyping
Company to expand its intellectual property portfolio in infectious disease testing.
Monday, May 21, 2012
Lab21 and ITOR Launch Clinical Genomics Center in USA
New Clinical Genomics Center will be located within the Greenville Hospital System (GHS) Memorial Medical Campus in Greenville, South Carolina.
Wednesday, March 07, 2012
Lab21 to Support New US Cancer Institute With Molecular Diagnostic and Clinical Trial Services
Lab21 announces an agreement with ITOR to provide molecular diagnostic support services for new initiatives in drug development and advanced cancer patient care.
Wednesday, October 20, 2010
Lab21 Launches new Commercial Companion Diagnostic Service for HIV Tropism in UK
Company becomes the first commercial reference laboratory in the UK to provide a companion diagnostic service for the HIV drug, Celsentri.
Tuesday, August 31, 2010
Lab21 and BreastHealth UK Form Partnership for Breast Health Management
The partners will offer UK women personalized health management and predictive genetic testing for breast cancer risk.
Wednesday, February 04, 2009
Lab21 Expands Companion Diagnostic Cancer Testing Service Internationally
Lab21 now offer its K-RAS gene mutation and its epidermal growth factor receptor mutation testing services to its international customers.
Friday, July 18, 2008
Lab21 Expands Cancer Gene Testing Service
Lab21 has now added an epidermal growth factor receptor mutation test to its existing range.
Friday, June 27, 2008
Lab21 Launches Cancer Gene Testing Service
Lab21 is providing a test for analysis of the K-ras gene that plays an important role in cell growth regulation and the proliferation of cancer cells.
Friday, January 25, 2008
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!